Syremis Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, dedicated to developing novel drug pipeline medicines targeted at treating diseases of the nervous system and mental health disorders.
Subscribe to see Syremis Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Syremis Therapeutics is a biotechnology company headquartered in Tel Aviv, Israel. Its most recent funding round, Series A, raised $165M in December 2025. Xcout tracks 4 named people at Syremis Therapeutics, including Elisabeth Kogan (co-founder and CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $165M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Syremis Therapeutics's closest competitors — see the full list of competitors and alternatives →
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Anacalypsis Therapeutics is a biotechnology innovation company based at the Athens Life Tech Park in Greece, focusing on developing medications and biomarkers for central nervous system diseases.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Awakn Life Sciences Inc. is a Canadian biotechnology and mental-health company developing psychedelic-assisted therapeutics, initially focused on ketamine-assisted therapy for alcohol use disorder and other addictions. It also operates or supports clinical and treatment services intended for patients with addiction and related mental-health conditions.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Syremis Therapeutics? Suggest a correction · Work at Syremis Therapeutics? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.